title: Progress in clinical neurosciences: Advances in the management of low-grade gliomas.
abstract: The management of low-grade gliomas represents one of the most challenging and controversial areas in neuro-oncology. Many aspects of the treatment of low-grade gliomas are debated, including the optimal timing of surgery and radiotherapy, the benefit of extensive surgery, and the impact of these variables on the natural history of these indolent and generally incurable tumours. The recently published results of several large multicentre trials addressing the timing and dose of radiotherapy have provided solid evidence for delayed and reduced dose irradiation. These studies have also confirmed prognostic variables that can be used to guide management of individual patients. Among these variables is the observation that tumours with oligodendroglial features have a better natural history and response profile. The recognition that as many as two thirds of low-grade gliomas have oligodendroglial features, advances in molecular diagnostics making accurate pathologic diagnosis of oligodendroglial tumours possible, and the established chemosensitivity of malignant oligodendrogliomas, have raised new issues surrounding the potential value of chemotherapy for low-grade gliomas. This review will be restricted to low-grade diffuse astrocytomas, oligodendrogliomas, and low-grade mixed oligoastrocytomas in adults, and provide evidence-based guidelines for the management of these tumours, including the emerging role of chemotherapy as initial treatment.
authors.affiliation: Department of Medical Oncology & Hematology, Princess Margaret Hospital, Toronto, Ontario, Canada.
authors.forename: Warren P
authors.initials: WP
authors.lastname: Mason
mesh_terms: D000328:Adult; D001932:Brain Neoplasms; D002986:Clinical Trials as Topic; D019317:Evidence-Based Medicine; D005260:Female; D005910:Glioma; D006801:Humans; D008297:Male; D011379:Prognosis